Skip to main content

NephroSant: Mark Capone

Mark Capone has joined the board of directors of NephroSant, a spinout from the University of California, San Francisco that is developing noninvasive testing solutions for kidney health. He is the president and CEO of Precision Medicine Advisors. Before that, he was president and CEO of Myriad Genetics, and prior to that, he held various positions at Eli Lilly. Capone holds a BS in chemical engineering from Penn State University and an MS in chemical engineering and in management from the Massachusetts Institute of Technology.